Alkermes plc announced plans to present two oral presentations and six posters from its industry-leading portfolio of sleep medicine research at the European Sleep Research Society’s (ESRS) 28th Congress, Sleep Europe 2026, taking place Oct. 20-23, 2026 in Maastricht, the Netherlands. The company will present new data related to LUMRYZ® (sodium oxybate) extended-release oral suspension, now part of Alkermes’ sleep portfolio following the acquisition of Avadel Pharmaceuticals plc, and alixorexton, Alkermes’ novel, investigational, oral, selective orexin 2 receptor (OX2R) agonist in development for the treatment of narcolepsy type 1 (NT1), narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH).
In an oral presentation, the company will present findings from the Vibrance‑1 phase 2 study of alixorexton in adults with NT1, which were recently published in The Lancet Neurology. The presentation will also include data from the open-label, long-term extension study evaluating the safety and durability of effect in participants with NT1 and NT2 who received alixorexton for up to nine months of treatment.
“I am pleased to present results from the Vibrance-1 phase 2 study and long-term extension evaluating alixorexton in patients with narcolepsy type 1 and type 2 at Sleep Europe. Together, these results further characterize the potential of alixorexton in narcolepsy and provide evidence supporting sustained clinical benefit with longer-term treatment,” said Giuseppe Plazzi, M.D., Ph.D., Neurologist, Director of the Narcolepsy Center at the IRCCS of the Neurological Sciences of Bologna and Professor of Childhood Neuropsychiatry at the University of Modena and Reggio Emilia.
In a separate oral presentation and corresponding poster presentation within the “Impactful Clinical Trial” session, the company will share detailed results from the phase 3 REVITALYZ study evaluating the investigational use of LUMRYZ in adults with IH. The Company previously announced positive topline results for this study.
“I am honored to present results from the REVITALYZ phase 3 trial evaluating LUMRYZ in adults with idiopathic hypersomnia, a chronic neurological disorder for which there are limited treatment options. It is an exciting time in sleep medicine, and the research being presented at Sleep Europe 2026 underscores the significant scientific progress we are seeing across narcolepsy and idiopathic hypersomnia,” said Richard Bogan, M.D., FCCP, FAASM, Principal of Bogan Sleep Consultants, LLC and Associate Clinical Professor at the University of South Carolina School of Medicine.
Additional Highlights to Be Shared in Poster Presentations at Sleep Europe 2026 Include:
- Results from An Interim Analysis of The Ongoing Open-Label, Long-Term Extension (lte) Study Evaluating the Safety and Maintenance of Effect of Alixorexton in Adults with Nt1 and Nt2 at Week 24 of The Lte, Approximately Nine Months After the First Dose for Participants Treated with Alixorexton in The Randomized Double-Blind Period of The Vibrance-1 and Vibrance-2 Phase 2 Studies;
- Exploratory Findings from The Vibrance-2 Phase 2 Study Evaluating the Impact of Alixorexton Compared to Placebo on Patient-Reported Measures of Cognition and Fatigue in Adults with Nt2;
- Detailed Study Designs and Methods for The Brilliance Studies, a Phase 3 Clinical Trial Program Evaluating the Safety and Efficacy of Alixorexton Compared to Placebo in Adults with Nt1 and Nt2; And
- Findings from Refresh, a Prospective Multicenter, Real-World Study in Adults with Narcolepsy, Including Patients Who Switched to Lumryz from A Twice-Nightly Oxybate and Patients New to Oxybate Treatment or Returning to Oxybate Treatment After Previously Discontinuing a Twice-Nightly Oxybate.
“the Breadth of Data Being Presented by Alkermes at Sleep Europe 2026 Reflects Both the Strength of Our Research Programs and Our Leadership in The Field of Sleep Medicine. We Look Forward to Sharing Detailed Findings from The Revitalyz Phase 3 Study of Lumryz in Patients with Idiopathic Hypersomnia, as Well as Initial Data from Our Long-Term Extension Study Evaluating the Durability of Effect of Alixorexton in Patients with Narcolepsy Type 1 and Type 2,” Said Craig Hopkinson, M.D. (mb Ch B), Chief Medical Officer and Executive Vice President, Research & Development at Alkermes. “through Our Ongoing Investment in Scientific Innovation Across Narcolepsy Type 1, Narcolepsy Type 2 and Idiopathic Hypersomnia, We Aim to Help Advance Differentiated Treatment Approaches and Address the Diverse Needs of People Living with These Serious Neurological Conditions.”
Details of Alkermes’ Presentations at Sleep Europe 2026 Are as Follows:
Revitalyz: A Phase 3, Double-Blind, Placebo-Controlled, Randomised Withdrawal Trial of Extended-Release Sodium Oxybate for Idiopathic Hypersomnia
- Presenter: Richard Bogan, M.D., Fccp, Faasm, Principal of Bogan Sleep Consultants, Llc and Associate Clinical Professor at The University of South Carolina School of Medicine
- Presentation Date: The Oral Presentation Is Scheduled to Occur on Friday, Oct. 23, 2026 from 12:10–12:30 Cest as Part of The “impactful Clinical Trial Session 1.” the Corresponding Poster (f314) Will Be Presented on Friday, Oct. 23, 2026 from 12:30–13:30 Cest.
Phase 2 and Long-Term Extension Results from Treatment with The Orexin 2 Receptor Agonist Alixorexton Demonstrated Clinically Meaningful Improvements in Symptoms of Narcolepsy Type 1 and 2
- Presenter: Giuseppe Plazzi, M.D., Ph.D., Head of The Sleep Center at The Institute of Neurological Sciences of Bologna, Italy and Chair of Child Neurology at The University of Modena and Reggio Emilia
- Presentation Date: The Oral Presentation Is Scheduled to Occur on Friday, Oct. 23, 2026 from 15:55–16:15 Cest as Part of The “hot Topics in Sleep Science and Medicine” Session.
Long-Term Safety, Tolerability, and Durability of Alixorexton: Interim Results from A Phase 2/3 Extension Study in Narcolepsy
- Poster Id: f304
- Presenter: Yves Dauvilliers, M.D., Ph.D., Professor of Neurology and Physiology, and Director of The Sleep-Wake Disorders Center at The University of Montpellier, France, and Coordinator of The French National Reference Center for Rare Diseases Dedicated to Narcolepsy and Hypersomnia
- Presentation Date: The Poster Will Be Presented on Friday, Oct. 23, 2026 from 12:30–13:30 Cest.
Participant-Reported Cognitive Functioning and Fatigue in Participants with Narcolepsy Type 2 Treated with Alixorexton, an Orexin 2 Receptor Agonist, in The Vibrance-2 Study
- Poster Id: w339
- Presenter: Richard Bogan, M.D., Fccp, Faasm, Principal of Bogan Sleep Consultants, Llc and Associate Clinical Professor at The University of South Carolina School of Medicine
- Presentation Date: The Poster Will Be Presented on Wednesday, Oct. 21, 2026 from 12:30–13:30 Cest.
Study Design for 2 Phase 3, Randomised, Double-Blind, Placebo-Controlled Studies Evaluating Alixorexton in Patients with Narcolepsy Type 1: The Brilliance Nt1 Studies
- Poster Id: w338
- Presenter: Julie Himes, M.D., Alkermes
- Presentation Date: Presentation Date: The Poster Will Be Presented on Wednesday, Oct. 21, 2026 from 12:30–13:30 Cest.
Study Design for A Phase 3, Randomised, Double-Blind, Placebo-Controlled Study Evaluating Alixorexton in Patients with Narcolepsy Type 2: The Brilliance Nt2 Study
- Poster Id: w337
- Presenter: Juan Chavez, M.D., Alkermes
- Presentation Date: The Poster Will Be Presented on Wednesday, Oct. 21, 2026 from 12:30–13:30 Cest.
Real-World Experience of Once-Nightly Sodium Oxybate Treatment in People with Narcolepsy: Final Results from Refresh
- Poster Id: t340
- Presenter: Jeremy Mc Connell, M.D., Florida Sleep Specialists
- Presentation Date: The Poster Will Be Presented on Thursday, Oct. 22, 2026 from 12:30–13:30 Cest
Source: Alkermes
